Cystinosis is an autosomal recessive disease in which three clinical forms are recognized: infantile nephropathic, with renal tubular damage by 1 year of age and progressive glomerular insufficiency; intermediate, with tubular and glomerular insufficiency beginning at a later age; benign, with no kidney damage. Skin fibroblasts cultured from patients with all types of cystinosis show increased intralysosomal free (nonprotein) cystine; however, fibroblasts from heterozygotes have normal free-cystine values. To determine whether genetic complementation occurs between the different forms, somatic cell hybrids were constructed between cells from a patient with infantile nephropathic cystinosis and cells from patients with other types ofcystinosis. Ifcomplementation occurred, the hybrids would be expected to have normal cystine levels. To construct hybrid cells, a "universal parent" cell type (TG1-neo), which was hypoxanthine/aminopterin/thymidine (HAT) sensitive and G418 resistant was constructed from an infantile nephropathic cystinosis fibroblast strain. Polyethylene glycol fusion of TG1-neo with other cells that are not HAT sensitive or G418 resistant allowed for selection of hybrid cells in a medium containing HAT and the aminoglycoside G418. As indicated by elevated cystine levels, complementation did not occur between TG1-neo and two different benign cystinosis strains, an intermediate cystinosis strain, or another nephropathic cystinosis cell strain. When a normal fibroblast strain was fused with TG1-neo, all 15 hybrid clones studied contained normal amounts of intracellular free cystine.
whether genetic complementation occurs between the different forms, somatic cell hybrids were constructed between cells from a patient with infantile nephropathic cystinosis and cells from patients with other types ofcystinosis. Ifcomplementation occurred, the hybrids would be expected to have normal cystine levels. To construct hybrid cells, a "universal parent" cell type (TG1-neo), which was hypoxanthine/aminopterin/thymidine (HAT) sensitive and G418 resistant was constructed from an infantile nephropathic cystinosis fibroblast strain. Polyethylene glycol fusion of TG1-neo with other cells that are not HAT sensitive or G418 resistant allowed for selection of hybrid cells in a medium containing HAT and the aminoglycoside G418. As indicated by elevated cystine levels, complementation did not occur between TG1-neo and two different benign cystinosis strains, an intermediate cystinosis strain, or another nephropathic cystinosis cell strain. When a normal fibroblast strain was fused with TG1-neo, all 15 hybrid clones studied contained normal amounts of intracellular free cystine.
Cystinosis is an autosomal recessive disease characterized biochemically by the accumulation of free (nonprotein) cystine within lysosomes (1) . The cystine accumulates in this location because of a defect in the normal egress ofthis amino acid from the lysosome to the cytosol (2-7). Three forms of cystinosis are recognized clinically: infantile nephropathic, with proximal tubular damage before 1 year of age and progressive glomerular insufficiency; intermediate (late onset), with tubular damage and glomerular insufficiency beginning at a later age; benign, with no kidney damage (1) . Further heterogeneity occurs within the intermediate form with an age of onset of =4 years in some families (8, 9) , 10-17 years of age in other families (10) (11) (12) (13) , and 25 years in one family (1) . Peripheral leukocytes and fibroblasts cultured from patients with all types of cystinosis show increased amounts of intralysosomal free (nonprotein) cystine. Although polymorphonuclear leukocytes from cystinotic heterozygotes contain increased amounts of free cystine (14) cultured fibroblasts from heterozygotes contain normal amounts of cystine (1) . The purpose of this study was to see whether somatic cell hybrids formed between fibroblasts from a patient with infantile nephropathic cystinosis and fibroblasts from patients with other forms of cystinosis would demonstrate correction of the defect-i.e., genetic complementation.
To search for genetic complementation between different forms of cystinosis, we required hybrid cells capable of prolonged growth so that enough cells could be obtained for study and a system that could select for the hybrid cells. We constructed such a cell in a stepwise process. First, a fetal nephropathic cystinosis cell strain was mutated with ethyl methanesulfonate and then, a 6-thioguanine-resistant hypoxanthine/aminopterin/thymidine (HAT)-sensitive cell was cloned. This cell strain was then transfected with pSV3-neo plasmid DNA and selected in the aminoglycoside G418. We refer to the resulting cell strain (TG1-neo) as a "universal parent," since it can be fused with any cell that is not "neomycin" (G418) resistant or HAT sensitive (presumably hypoxanthine phosphoribosyltransferase negative). Only the hybrid can exist in G418 and HAT medium.
TG-1 neo was fused with five other cell types: a normal, an intermediate cystinotic, two benign cystinotics, and another infantile nephropathic cystinotic. In addition to cystine measurement, additional characterization included chromosome studies, HLA marker analysis, and, in one set of hybrids, glucose-6-phosphate dehydrogenase isoenzyme analysis.
MATERIALS AND METHODS
Fibroblast Cell Strains. Human diploid fibroblasts were grown on culture dishes (Lux) in Coon's modified Ham's F-12 medium (Irvine Scientific) with 10% fetal bovine serum (Irvine Scientific) (15) . Hybrids were cultured in the same media with HAT (16) and G418 (0.1 mg/ml) added (17) . The fibroblast cultures used were from a fetus with infantile nephropathic cystinosis (18) , from a Black patient with the same type of cystinosis (19) , from a patient with intermediate cystinosis, and from two unrelated patients with benign cystinosis. The normal control fibroblast culture was started from the foreskin of a normal male infant.
Mutation and Transfection. Fetal skin fibroblasts from a patient with nephropathic cystinosis (F.S.J.) (18) were treated with 2.15 mM ethyl methanesulfonate for 24 hr and selected in 30 ,uM 6-thioguanine. One clone from this selection was then used for the transfection. This clone was resistant to 6-thioguanine and sensitive to HAT. For transfection, 106 cells per 100-mm plate were treated with 20 ,ug of pSV3-neo plasmid DNA (without carrier DNA) in the presence of calcium phosphate (17) genase activity between the A and B isoenzymes (data not shown). This provides independent evidence that the cells studied were hybrid cells (16) . Chromosome analysis of TG1-neo showed it to be aneuploid with a median chromosome number of 60. All cells crossed to TG1-neo were diploid (or near diploid). Analysis of chromosome spreads from the hybrid clones showed median chromosome counts ranging from 64 to 91 (mean ± SD; 73 ± 8) in TG1-neo x Bas (the normal control cell) and from 56 to 96 (72 ± 10) in TG1-neo x the various cystinotic cell types used. In the hybrids, many spreads could not be counted accurately because of chromosome "overlap." Since these represented primarily those with the greatest numbers of chromosomes, the reported values are underestimates.
The cystine content of all the cystinosis x cystinosis clones analyzed was in the typical cystinotic range no matter which type of cystinosis was fused with TG1-neo ( Table 2 ). All clones of normal (Bas) x TG1-neo had a cystine content within the range of normal fibroblasts. There was no correlation between cystine content and median chromosome number in any of the hybrid clones.
DISCUSSION
Since Cogan et al. described the first case of benign cystinosis in 1957, many other cases have been reported (23) (24) (25) (26) (27) (28) (29) (30) . Investigators have attempted to explain why these patients, who have accumulations of cystine crystals in many of the same tissues as patients with nephropathic cystinosis, do not have renal damage. The first biochemical difference noted in patients with benign cystinosis was that the cystine content of their leukocytes, although elevated, was not elevated to the same range as in patients with infantile nephropathic cystinosis (8, 26) . Kidney biopsy samples from two patients with benign cystinosis demonstrated no cystine crystals (24, 29) , and the cystine content of the one biopsy sample measured was not elevated (29) . Thus, it seems that renal function is normal in patients with the benign form of cystinosis because their kidneys do not accumulate cystine.
Patients have also been reported with an intermediate form of nephropathic cystinosis (8) (9) (10) (11) (12) (13) (31) (32) (33) . Unlike patients with benign cystinosis, these patients do have renal dysfunction. They differ from patients with infantile cystinosis because their disease is not apparent until an older age, they frequently do not have the complete Fanconi syndrome, and their glomerular insufficiency progresses more slowly. The age at which their first symptoms are noted has ranged from 4 to 25 years (1). When more than one individual in a sibship has this condition, the age of onset of symptoms is similar. These facts suggest that the intermediate form of nephro- 18- week-old fetus with the infantile form of cystinosis contained 100 times the normal cystine content, yet the histology of this fetal kidney was normal (18) . When followed very carefully from birth, the earliest age at which any renal abnormalities can be detected in infantile cystinosis is 4-6 months (34, 35 (37, 38) . Both of these studies showed apparent return of hexosaminidase activity after such fusion. A study of heterokaryons that were formed between fibroblasts from patients with Hurler, Scheie, and Hurler-Scheie compound syndrome showed no return of a-L-iduronidase activity and thus was taken as evidence that these conditions were allelic mutants (39) . Heterokaryon formation between fibroblasts from patients with the infantile, juvenile, and adult onset forms of Gaucher disease yielded similar results. The heterokaryons formed remained deficient in acid P-glucosidase activity, and this was taken as evidence that these mutations occur in a single gene (40, 41 (17) .
The chromosome loss in hybrid clones was greater in this study, in which cystinotic fibroblasts were fused with TG1-neo, than in our previous study, in which cystinotic fibroblasts were fused with HeLa cells. In the latter study, the hybrids lost -10% of their parental chromosomes, whereas in the present study the loss averaged -30%. The lack of complementation in the cystinotic x cystinotic crosses could only be explained by this chromosome loss if one set of homologous chromosomes (the chromosome that contains a defective gene for cystinosis) from either TG1-neo or the other cystinotic parent was lost in each of the 27 cystinosis x cystinosis clones. Although this possibility cannot be ruled out, it seems unlikely. Such a pair of homologues were clearly not lost from the normal parent in the TG1-neo x Bas cross, since this would have prevented the observed correction of cystine content.
Since we constructed only one "universal parent," from a fibroblast from a patient with infantile cystinosis, we were not able to construct every possible hybrid cross. However, we were able to show that no complementation occurred between cells from a patient with typical infantile nephropathic cystinosis, a Black patient with the same defect, a patient with intermediate cystinosis, or two unrelated patients with benign cystinosis. The lack of complementation in any of these crosses strongly suggests that these defects are allelic.
